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ArteriosclerosisMitochondrial membrane architecture is important for organelle function. Alterations thereof are linked to a
number of human disorders including diabetes and cardiomyopathy. The MICOS complex was recently reported
to be a central player determining cristae structure and formation of crista junctions. Here we investigated the
functional role of MIC26, a lipoprotein formerly termed APOO. Its levels are increased in diabetic heart tissue
and in blood plasma of patients suffering from acute coronary syndrome. We demonstrate that human MIC26
exists in three distinct forms: (1) a glycosylated and secreted 55 kDa protein, (2) an ER/Golgi-resident form
thereof, and (3) a non-glycosylated 22 kDa mitochondrial protein. The latter isoform spans the mitochondrial
inner membrane and physically interacts with several MICOS complex subunits such as MIC60, MIC27, and
MIC10.We further demonstrate that MIC26 andMIC27, a homologous protein formerly termed APOOL, regulate
their levels in an antagonistic manner. Both proteins are positively correlated with the levels of MIC10 as well as
tafazzin, an enzyme required for cardiolipin remodeling. Overexpression of MIC26 induced fragmentation of
mitochondria, promoted ROS formation and resulted in impaired mitochondrial respiration. Downregulation of
MIC26 induced a decrease in mitochondrial oxygen consumption, whereas mitochondrial network morphology
and ROS levels remained unaffected. MIC26 depletion led to alterations in mitochondrial ultrastructure and
caused a signiﬁcant reduction in the number of crista junctions. In summary, we show that the human apolipo-
protein MIC26 is a bona ﬁde subunit of the MICOS complex and that MIC26 is linked to cardiolipin metabolism
and promotes crista junction formation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The architecture ofmitochondrialmembranes is highly complex and
of fundamental importance for organelle function and integrity [1]. Al-
tered inner membrane morphology is observed in a number of human
disorders such as diabetes [2–4], various neurodegenerative diseases
[5,6] and other systemic disorders [7–9]. In order to better understand
the link between mitochondrial membrane architecture and those
disorders it is essential to identify and characterize novel factors main-
taining mitochondrial ultrastructure and function. Mitochondria are
enclosed by two membranes: the outer membrane (OM) and the
inner membrane (IM). The latter is further subdivided into the inner
boundary membrane (IBM) and the cristae membrane (CM). The IBM,
which is adjacent to the OM, is linked by narrow circular- or slit-like
connections, termed crista junctions (CJs) to the CM. CJs are proposed
to constitute a diffusion barrier between the IBM and the CM as well
as between the lumen enclosed by the CM and the lumen limited byd Molecular Biology I, Heinrich
40225 Düsseldorf, Germany.OM and IBM [10–12]. By that they are believed to e.g. regulate the diffu-
sion of ADP required for ATP synthesis or the release of pro-apoptotic
proteins of the IMS such as cytochrome c [13,14]. This view is supported
by several studies showing that the protein composition between CM
and IBM differs considerably [15–17]. The IBM is enriched for proteins
mediating inner membrane fusion [18,19], import of nuclear-encoded
proteins [20], and synthesis of certain lipids [21]. Conversely, complexes
and supercomplexes of the respiratory chain [22,23] and the F1FO-ATP
synthase [24] are enriched in the CM. In order to generate these distinct
subcompartments mitochondrial membranes apparently need to be
shaped by protein scaffolds and certain lipids. The mitochondrial spe-
ciﬁc diphosphoglycero-lipid cardiolipin (CL) was described to occur in
both mitochondrial membranes, but predominantly at its production
site within the mitochondrial IM [25,26]. CL has been reported to be
essential for function of various OXPHOS complexes, formation of the
CICIII2CIV2supercomplex, and F1FO-ATP synthase assembly and mem-
brane integration [27–29]. CL is synthesized starting from ER-derived
phosphatidic acid (PA) by an enzymatic cascade located in the IBM.
Immature CL is further remodeled by the transacylase tafazzin (TAZ1)
via an intermediate, monolyso-CL (MLCL), which is subsequently
matured to structurally uniform and symmetric CL [30]. Chromosomal
mutations within the TAZ1 locus lead to the mitochondrial disorder
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decreased CL and increased MLCL levels resulting in reduced cristae
density and inhomogeneous cristae distribution [32]. Besides the struc-
tural alterations of the CM loss of TAZ1 leads to a decrease in respiratory
chain function [33]. CL is known to be essential formembrane shape and
protein function in different mitochondrial membranes including the
OM and the CM. Thus, as it is apparently synthesized in the IBM, it
must be transported to the OM and the CM, respectively. We recently
could demonstrate that MIC27, a member of the apolipoprotein family
formerly termed apolipoprotein O-like (APOOL), is located in the IM/
IMS of mammalian mitochondria and binds speciﬁcally to CL [34].
MIC27 was found as a constituent of theMICOS complex, a high molec-
ular weight complex located at CJs [34]. Initially, this complex was
described in baker's yeast and termed FCJ1, MINOS, MitOS, or MiCoS
complex [35–38]. To avoid further confusions this complexwas recently
renamed to ‘mitochondrial contact site and cristae organization system‘
(MICOS) and a uniﬁed nomenclature for its subunits was proposed
using the three letters Mic or MIC followed by the apparent molecular
weight of the proteins [39]. MIC60/Mitoﬁlin was shown to affect forma-
tion of CJs and cristae morphology in mammalian cells [40]. Mic60/Fcj1
from Saccharomyces cerevisiae was the ﬁrst subunit identiﬁed as a
subunit of a high molecular weight complex localizing to CJs and to be
directly involved in CJ formation [35]. MIC60 is conserved among differ-
ent eukaryotic species and ensures normal architecture of CJs in several
organisms [8]. Up to date six subunits are known for the yeast MICOS
complex: Mic60, Mic27, Mic26, Mic19, Mic12, and Mic10 [35–39].
Concerning the mammalian MICOS complex only four subunits have
been demonstrated so far to constitute this complex: MIC60/Mitoﬁlin
[40], MIC27/APOOL [34], MIC19/CHCHD3 [41], and MIC10/MINOS1
[42]. For the two homologous proteins Mic26 and Mic27 from
S. cerevisiae also two homologs in mammals exist, namely apolipopro-
tein O (APOO) and MIC27 (APOOL). In an earlier study we could show
that overexpression or depletion of MIC27 led to alterations in mito-
chondrial ultrastructure. MIC27 was discussed to play several roles
linked to CL biology including a role in CL transport within mitochon-
drial subcompartments [43]. For bovine APOO we could show by
using a complexome proﬁling approach that it comigrated under native
conditions with MIC27 and other subunits of the MICOS complex [34].
However, direct evidence that APOO is truly a subunit of the MICOS
complex was lacking. APOO was earlier shown to be an apolipoprotein
as it is secreted as a glycosylated apolipoprotein present primarily
in HDL particles [44,45]. It is upregulated in heart tissue of diabetes
patients and promotes cholesterol efﬂux from mouse macrophage
J774 cells in vitro. Based on this, it was proposed to protect from
lipoapoptosis in the diabetic heart and to act in an anti-atherogenic
manner [44]. Nevertheless, another study reported that overexpression
of APOO does not affect HDL-mediated cholesterol transport signiﬁ-
cantly [46]. Plasma APOO levels are also increased in animals fed by a
high-fat diet and in patients suffering from acute coronary syndrome
(ACS) [45,47]. Recently, APOO was proposed to be implicated in the
metabolismof fatty acidswithinmitochondria [48,49]. As a glycosylated
protein within mitochondria would be unexpected, we decided to
characterize APOO in more detail. Based on our results and according
to the novel uniﬁed nomenclature for the MICOS complex [39] we
decided to term it MIC26 from now on. Here, we show that MIC26 has
rather distinct cellular localizations: on the one hand it is directed
to the ER and Golgi where it becomes glycosylated along the secretory
pathway (MIC2655kDa), on the other hand its non-glycosylated form
(MIC2622kDa) is targeted to mitochondria. Within mitochondria
MIC2622kDa spans the IM and exposes major parts to the matrix side.
Due to its physical interaction with multiple MICOS subunits such as
MIC60, MIC27 and MIC10, we propose that MIC2622kDa is a novel
constituent of the MICOS complex. Moreover, MIC2622kDa reciprocally
regulates MIC27 levels and modulates MIC10 and tafazzin levels. Over-
expression of an myc-tagged version of MIC26 induced fragmentation
of mitochondria and an increase in mitochondrial ROS levels and isfurther shown to impair mitochondrial respiration. MiRNA-mediated
knockdown ofMIC26 resulted in a decrease in basal respiration as well
as in a decreased maximal respiration capacity. MIC26 depletion leads
further to an altered appearance of cristae membranes and a reduced
number of CJs. Our results suggest that MIC26 plays a crucial role for
crista junction formation and mitochondrial function.
2. Materials and methods
2.1. Cell culture
Cells have been cultured in MEM medium (MEM-M4655, Sigma)
containing 1 g/l glucose supplemented with 10% fetal calf serum (FCS,
Sigma), 1 mM sodium pyruvate (Gibco), 1% non-essential amino acid
solution (Sigma) and 1% penicillin/streptomycin solution (100 U/ml,
Gibco). Incubation was performed constantly at 37 °C and 5% CO2. For
analysis either 143B osteosarcoma cells (ATCC-# CRL-8303), HeLa
cells (ATCC-# CCL-2, kindly provided by Dr. Martin Vabulas, BMLS
Institute, Frankfurt) or HepG2 hepatocellular carcinoma cells (ATCC-#
HB-8065, kindly provided by Prof. Ernst Stelzer, BMLS Institute,
Frankfurt) were used. Transient gene transfection was performed
using Effectene nonliposomal lipid reagent (Qiagen) according to
manufacturer's instructions. To generate stable cell lines constitutively
expressing transcript targeted miRNAs we performed antibiotic selec-
tion using 10 μg/ml blasticydin (Life Technologies) after two times of
transient transfection. To generate pure cell lines wemanually singular-
ized cells exploiting the EmGFP ﬂuorescent marker.
2.2. Plasmids and constructs
For overexpression the humanMIC26 (APOO) sequence was ampli-
ﬁed from HeLa cDNA and cloned into the pcDNA3.1 vector (Invitrogen)
using the following primers (forward: 5′-XhoI_ATGGAGCAGAAGCTCAT
CTCAGAAGAAGACCTCGAGATGTTCAAGGTAATTCAGAG; reverse: 5′-
XbaI_AAATCTAGACTACTTAGTTCCAGGTGAATT) and fused to an N-
terminal MYC-sequence. The construct of human MIC27 (APOOL)
cloned into pcDNA3.1 and carrying a C-terminal FLAG-tag used for over-
expression of MIC27 was described earlier [34]. For RNA interference
experiments MIC26 speciﬁc miRNA targeted against nucleotide posi-
tions 406 to 426 of the coding sequence of MIC26 was constructed
using the following oligos provided by Invitrogen (miRNA_643_TOP
TGCTGAAACCAGGCGGATACACTACGTTTTGGCCACTGACTGACGCTAGT
GTCCGCCTG; miRNA_643_BOTTOM CCTGAAACCAGGCGGACACTAGCG
TCAGTCAGTGGGCCAAAACGCTAGTGTAT CCGCCTGG). We cloned these
double-stranded oligos into the linearized pcDNA6.2/EmGFP-miR
vector using the BLOCK-it PolII RNAi Kit according to manufacturer's in-
structions (Invitrogen). AMIC27 targeted miRNA construct comprising
the same vector backbonewas described earlier [34]. As a negative con-
trol we used a control plasmid carrying the cytosolic EmGFP ﬂuores-
cence marker as provided by the manufacturer. Generation of an
miRNA resistant form ofmyc-MIC26was done as described [50].
2.3. Cellular fractionation
To perform cellular fractionation cells were washed with PBS
(Sigma), harvested by accutase (PAA) treatment and pelleted at
500 ×g. The pellet was resuspended in isotonic buffer (210mMmanni-
tol, 70 mM sucrose; 0.5 mM EDTA and 10 mM HEPES, pH 7.5) in the
presence of protease inhibitor cocktail (Roche). Cells were lysed by
mechanical rupture using a syringe and a 20G cannula. Within a ﬁrst
fractionation step of 1000 ×g the cell debris and nuclei were separated
from the heavymembrane containing supernatant. To pellet mitochon-
dria the supernatant was subsequently centrifuged at 7000 ×g. To pellet
ER fractions and light membranes the supernatant was repeatedly
centrifuged at 100,000 ×g for 1 h. The remaining supernatant containing
cytosolic componentswas subsequently precipitated using 10% trichloric
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(300 mM trehalose; 10 mM HEPES, pH 7.5; 10 mM KCl; 1 mM EDTA;
0.1% (w/v) BSA) for storage at -20 °C or used immediately for further
analysis. ER or cytosolic fractions were directly mixed with Laemmli
loading buffer and used for SDS-PAGE.2.4. Submitochondrial localization experiments
Mitochondria were isolated in isotonic buffer in the absence of
protease inhibitor cocktail. Mitochondria (50 μg) were digested on ice
with 10 μg trypsin for 30 min with increasing amounts of digitonin
applying a detergent:protein ratio ranging from 0.25:1 to 4:1 (w/w).
As a control cells were solubilized in 1% Triton X-100 (w/w) and proc-
essed the same way. Protein digestion was stopped using 100 mM
phenylmethylsulfonyl ﬂuoride (PMSF) and samples were subsequently
prepared for SDS-PAGE. Carbonate extraction was performed using
0.1 M freshly prepared sodium carbonate solution (pH 11.3) and 50 μg
mitochondria and other heavy membranes were incubated on ice for
30 min. Membrane proteins were separated from soluble proteins by
centrifugation at 16,000 ×g for 20 min. The supernatant was carefully
removed from the membrane pellet fraction and both fractions were
prepared for SDS-PAGE in Laemmli loading buffer [51].2.5. Analysis of MIC2655kDa secretion and glycosylation
For analysis of MIC2655kDa secretion cells were seeded in a 6-well
plate to a constant density of 1 × 106 cells per well 1 day prior to treat-
ment. The following day growthmediumwas exchanged toMEMwith-
out FCS and increasing amounts of the microsomal triglyceride transfer
protein (MTTP) inhibitor naringenin (Sigma) diluted in DMSO were
added. After 24 h an aliquot of the cell medium containing secreted pro-
teins was precipitated with 10% trichloric acetic acid (TCA). Cells were
harvested by accutase treatment and samples were prepared for SDS-
PAGE and immunoblotting. MIC2655kDa glycosylation was analyzed
using chondroitinase ABC (Sigma) puriﬁed from P. vulgaris. Fifty micro-
grams of cell lysates was resuspended in assay buffer (20 mM Tris,
pH 8.8; 0.05 mM sodium acetate and 0.01% (w/v) BSA) and 0.25 U/ml
chondroitinase ABC was added to enzymatically remove O-glycosidic
bound carbohydrates. After incubation at 37 °C for 2 h the reaction
was stopped with 1 mM ZnSO4.2.6. Co-immunoprecipitation (Co-IP)
Protein G sepharose beads (GE Healthcare) for a MIC26 antibody
raised in mouse (APOO, Thermo Scientiﬁc, MA5-15493), or protein
A sepharose beads (GE Healthcare) for MIC27 (APOOL, Atlas Anti-
bodies, HPA000612) and MIC60 (Pineda, Berlin, polyclonal anti-
body raised in rabbit against human IMMT using the peptide
CTDHPEIGEGKPTPALSEEAS) antibodies both raised in rabbit were
used for Co-IP experiments. Beads were equilibrated in IP-buffer 1
(20 mM HEPES, pH 7.5; 100 mM NaCl; 10% glycerol; 5 mM MgOAc;
1% (w/v) BSA) and carefully prepared for antibody coupling. Onemicro-
gram of antibody or preimmune serum (PI) was applied to beads and
incubated for binding on anorbital rotor at 4 °C overnight.Mitochondria
were isolated from 143B or HeLa cells and 350 μg mitochondria were
solubilized at a digitonin:protein ratio of 4:1. Solubilized proteins
were separated frommitochondrialmembrane debris by centrifugation
at 16,000 ×g for 15 min at 4 °C. The supernatant was added to the
antibody-bound beads and incubated by rotating at 4 °C for up to 4 h.
The beads were washed three times with IP-buffer 2 (IP buffer 1 with
0.1% (w/v) digitonin) and proteins were eluted with 2× Laemmli
sample buffer for 5 min at 95 °C. Analysis was done by SDS-PAGE and
subsequent immunoblotting.2.7. SDS-PAGE and western blot analysis
For discontinuous SDS-PAGE 10% tricine gels were casted using Tris–
SDSbuffer (1MTris–HCl, pH8.45; 0.1% SDS [52,53]). Protein amounts of
total cell extracts ormitochondriawere determined by Bradford protein
assay and adjusted in Laemmli loading buffer. Samples were boiled
at 95 °C prior to gel loading for 5 min. Running of SDS-PAGE was done
according to Schägger et al. [52,53] and proteins were transferred to
nitrocellulose membranes. For immunoanalysis the following anti-
bodies have been used for decoration: β-actin (Cell Signaling, #4967
or Thermo-Fisher, MAB-Gea), HSP60 (Cell Signaling, #4870), TOM20
(Atlas Antibodies, HPA011562), MIC27/APOOL (Atlas Antibodies,
HPA000612), MIC26/APOO (Thermo-Fisher, MA5-15493) MIC60/
Mitoﬁlin (Pineda, Berlin, polyclonal antibody raised in rabbit against
human IMMT using the peptide CTDHPEIGEGKPTPALSEEAS), MIC10/
MINOS1 (Pineda, Berlin, polyclonal antibody raised in rabbits against
CQHDFQAPYLLHGKYVK), MIC19/CHCHD3 (abcam, ab69328), OPA1
(Pineda, Berlin, polyclonal antibody raised in rabbits against the C-
terminus of human OPA1 using the synthetic peptide CDLKKVREI
QEKLDAFIEALHQEK), human TAZ1 (gift from Steve Claypool), FLAG
(Gilbertsville, USA or Sigma-Aldrich, s3165), and MYC (Millipore,
#05724). Recording and quantiﬁcation of chemiluminescent signals
were done using the ChemiDoc XRS+ system and the corresponding
Image Lab quantiﬁcation software version 4.0.1 (BioRad).
2.8. Fluorescence microscopy and analysis of mitochondrial morphology
Cells were cultured on coverslips 1 day prior to cell treatment or
transient transfection. Cells were ﬁxed using 3.7% formaldehyde diluted
in culture medium at 37 °C, followed by a cell permeabilization step in
ice coldmethanol at−20 °C for 20min. Unspeciﬁc bindingwas blocked
(3% (w/v) BSA, 0.02% (v/v) Triton X-100 in PBS) prior to antibody or
DAPI staining. To determine mitochondrial morphology cells were
stained using either 50 nMMitotracker Red (MTR, Invitrogen) or immu-
nostainingwas carried out using anti-cytochrome c Alexa Fluor-555 (BD
Bioscience). Between all incubation steps samples were washed 2–3
timeswith PBS. Mitochondrial morphology from ~200 cells was catego-
rized as described previously [34]. Quantiﬁcation was done using three
independent experiments. Images were takenwith a Leica TCS SP5 con-
focal laser-scanning microscope (DMI6000) at the appropriate spectral
settings using a diode laser (405 nm excitation, 450/15 nm detection),
an argon laser (488 nm excitation, 515/30 nm detection) and a HeNe
laser (543 nm excitation, 605/75 nm detection). The applied objective
was an HCX PL APO lambda blue 63.0 (Leica), with a 1.40 numerical
aperture oil immersion lens. All recorded pictures were analyzed
using the Leica AF software 2.6.3.8173 and the ImageJ software.
2.9. Determination of ROS levels
To determine superoxide anion levels HeLa or 143B cells were seeded
24–48 h prior to measurement in a 96 black well optical bottom plate
(ThermoScientiﬁc) with a constant density of 3–5 × 104 cells per well.
At the day of measurement the ﬂuorescent dye dihydroethidium (DHE)
was supplemented to the medium in a ﬁnal concentration of 5 μM and
the cells were incubated for 30 min. As control cells were starved for
4 h prior to DHE supplementation in HBSS leading to an induction of
mitochondrial ROS. After DHE incubation medium was exchanged to
PBS and DHE derived ﬂuorescence was measured using an Inﬁnite
M200Pro plate reader (Tecan, Germany), with an excitation wavelength
set to 518 nm and an emission wavelength set to 605 nm. Z-position
was determined automatically by the Tecan i-control software 1.9.
2.10. Determination of oxygen consumption rate (OCR)
To measure the O2 consumption rate of adherent HeLa or 143B cells
an XF24-3 Extracellular Flux Analyzer (Seahorse Bioscience) was used.
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with a constant density of 3–5 × 104 cells per well 24 h prior to mea-
surement. The sensor cartridge was preincubated according to
manufacturer's instructions overnight. The next day the reagent deliv-
ery chambers of the sensor cartridge were preloaded with DMSO as a
control, and stock solutions of the F1FO-ATP synthase inhibitor oligo-
mycin (ENZO), the uncoupler carbonyl-cyanide-(triﬂuoromethoxy)-
phenylhydrazone (FCCP; Sigma-Aldrich) or the complex I inhibitor
rotenone (Sigma-Aldrich). After preincubation at 37 °C without CO2
the measurement was started and for each cell line at least four inde-
pendent wells were analyzed. Final assay concentrations of 2.5 μM
oligomycin, 10 μM FCCP and 1 μM rotenone in a volume of 650 μl per
well were applied. Basal respiration as well as background correction
was calculated using the XF24 Extracellular Analyzer software 1.8.1.
2.11. Electron microscopy
Cells were cultured on a Petri dish to 80% conﬂuence and chemically
ﬁxed with 3% glutaraldehyde buffered in 0.1 M sodium cacodylate
buffer, pH 7.2. Cells were harvested with a cell scraper, washed with
0.1 M sodium cacodylate buffer, pH 7.2, and embedded in 1.5% agarose.
Staining was performed with 1% osmium tetroxide for 50min and with
1% uranyl acetate overnight. Dehydration of samples was done using
graded ethanol series. Specimens were embedded in LV epoxy resin
and incubated for polymerization at 65 °C for 16 h. Sections were
inspected with a transmission electron microscope (EM 208S, FEI) at
80 kV. A 1 k × 1 k slow-scan camera (TVIPS, Tietz) was used for image
acquisition.
2.12. Bioinformatic sequence analysis and statistics
MIC26 sequence analysis was done using GeneBank (NCBI); or
TargetP 1.1 (Technical University of Denmark) as well as MitoProtII –
v1.101 for signal sequence analysis. Possible O-glycosylation sites
were predicted by the NetOGlyc Server 4.0 considering amino acid
residues with a probability score of N50.49%. Statistics for all experi-
ments were done applying a two-tailed unpaired Student's t-test giving
p-values of *p b 0.05, **p b 0.01 and ***p b 0.001.
3. Results
3.1. MIC26 is a non-glycosylated mitochondrial protein (22 kDa) as well as
a glycosylated protein (55 kDa) secreted to the extracellular space
Bioinformatic sequence analysis predicted MIC26 (formerly termed
human APOO, FAM121B or My025) as a protein of 198 amino acids
and a molecular mass of 22 kDa. MIC26 contains a conserved sequence
domain of the APOO superfamily harboring one hydrophobic domain
(Fig. 1A). Applying different subcellular targeting prediction algorithms
(see Section 2) suggested that MIC26 can potentially localize to mito-
chondria or to be alternatively targeted via the secretory pathway. As
a secretory protein MIC26 is predicted to be posttranslationally modi-
ﬁed by an O-glycosidic attachment of carbohydrates with the highest
probability at serine residues S34, S41 and S50.
In previous studies HepG2 cells were used to study MIC26 localiza-
tion and function [44,46,48,54]. To investigate the subcellular localiza-
tion of MIC26 we analyzed similar amounts of protein lysates from
three different cell lines including HepG2 cells (Fig. 1B). In all cell lines
we detected two isoforms of MIC26 in the crude mitochondrial fraction
(M) of differentmolecularweight, namely onewith its predictedmolec-
ular weight of 22 kDa (MIC2622kDa) and one larger formwith a molecu-
lar size of 55 kDa (MIC2655kDa). Strikingly, no MIC2622kDa was detected
in any of the supernatant fractions (S) of the three cell lines. The super-
natant contains soluble proteins and light membranes such as ER-,
Golgi-, liposomal or plasma membranes. MIC2655kDa was strongly
enriched in these fractions. To test whether MIC2655kDa or MIC2622kDaobserved in the crudemitochondrial fraction (M)was a result of impure
mitochondria copuriﬁed with light membranes of the ER or Golgi we
performed subcellular fractionation from 143B lysates in a way that
allowed the separation of membranes from these organelles. We could
demonstrate that MIC2655kDa is clearly enriched in the ER/Golgi mem-
brane fraction similar to the ER-associated protein calreticulin (CRN)
(Fig. 1C). Furthermore, MIC2655kDa appears to behave differently to
the glycosylated lysosome-associated membrane protein LAMP1. Im-
portantly, MIC2622kDa was clearly excluded from the ER/Golgi fraction
and was speciﬁcally detected in the mitochondrial fraction (M) as indi-
cated by the mitochondrial marker protein TOM20 (Fig. 1C). In sum-
mary, these results depict a dual localization of MIC26: MIC2622kDa as
a mitochondrial protein and MIC2655kDa as a protein associated with
the secretory pathway.
MIC2655kDa has been described earlier to be O-glycosylated in
HepG2 cells [44]. To test whether the size shift in HeLa cells indeed
comes from an O-glycosylation of MIC26 we performed an in vitro
deglycosylation experiment using chondroitinase ABC. We could show
that the enzyme removes speciﬁcally O-glycosidic bound carbohydrates
from MIC2655kDa, releasing unmodiﬁed MIC2622kDa (Fig. 1D). Taken to-
gether, our data indicate that MIC2655kDa represents an O-glycosylated
form.
Since glycosylated proteins commonly pass the secretory pathway
we tested to which extent MIC2655kDa is secreted by HepG2 and 143B
cells. To block MIC2655kDa secretion we added naringenin, a potent
inhibitor of microsomal triglyceride-transfer protein (MTTP) [44]. We
analyzed the level of MIC2655kDa secreted to the culture medium and
compared it to intracellular levels of MIC2655kDa and several marker
proteins (Fig. 1E). Secretion of MIC2655kDa was observed in both cell
lines and was inhibited by naringenin in a dose dependent manner.
Notably, intracellular MIC2655kDa is well detectable in HepG2 cells but
hardly in cell lysates from143B cells. Likewise,MIC2655kDa gets secreted
to a much higher extent from HepG2 cells compared to 143B cells. In
contrast, the protein levels of MIC2622kDa are increased in 143B cells
compared to HepG2 cells indicating a possible cell-line dependent reg-
ulation of MIC2622kDa and MIC2655kDa levels. Also the level of MIC27,
the homolog of MIC26 which apparently is only localized to mitochon-
dria [34], is higher in 143B cells than in HepG2 cells. We conclude that
MIC26 is both a glycosylated protein passing the secretory pathway
as well as a mitochondrial protein; yet, the relative amounts of these
isoforms are cell-type speciﬁc.3.2. MIC2622kDa is an integral protein of themitochondrial inner membrane
To localize MIC2622kDa we overexpressed myc-tagged MIC26 in
HeLa cells. The tagged variant of MIC26 is largely non-glycosylated
as conﬁrmed by western blot analysis and thus represents the myc-
MIC2622kDa isoform (Fig. 2A, WB panel). Next we performed immuno-
ﬂuorescence microscopy using a monoclonal MIC26 antibody. We
observed a clear colocalization of MIC26with themitochondrialmarker
Mitotracker Red (MTR) indicating that myc-MIC2622kDa is indeedmain-
ly located in mitochondria (Fig. 2A, ﬂuorescence pictures). Diffuse ﬂuo-
rescence within the cytosol of transfected cells and untransfected cells
can be attributed to endogenous MIC26 localized to membranes of the
ER or Golgi apparatus or to background ﬂuorescence.
To corroboratewhether endogenousMIC2622kDa is localized tomito-
chondria, we performed subcellular fractionation followed by western
blot analysis. EndogenousMIC2622kDa was present in themitochondrial
fraction as indicated by themitochondrialmarkers OPA1,MIC60,MIC27
and HSP60 (Fig. 2B). Moreover, MIC2622kDa was absent in the cytosolic
fraction (C) similar to other mitochondrial marker proteins. Actin, a
cytosolic marker, was enriched in the cytosolic fraction but was also
found to partly co-purify with the mitochondrial fraction. The latter is
not unusual as actin is known to bind mitochondria and plays a role in
mitochondrial motility [55].
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sentative for each compartment. MIC2655kDa is localized to the ER/Golgi fraction whereas MIC2622kDa is exclusively found in mitochondria. T, total lysates, M, mitochondrial fraction, ER/
Golgi, lightmembrane fraction enriched in calreticulin (CRN) and glycosylated lysosomal-associatedmembrane protein 1 (LAMP1), C, cytosolic fraction; as amitochondrialmarker TOM20
was used. D,MIC26 deglycosylation experiment using chondroitinase ABC. Actin served as a loading control. E, Intracellular and extracellular levels ofMIC26 andMIC27 in HepG2 or 143B
cells. Mitochondrial HSP60 was used as a loading control. Naringenin was used to inhibit protein secretion.
1555S. Koob et al. / Biochimica et Biophysica Acta 1853 (2015) 1551–1563To investigate the submitochondrial localization of MIC2622kDa
we next performed a protease protection assay using mitochondria
isolated from 143B cells. To achieve a step-wise solubilization of mem-
brane proteins we used increasing amounts of digitonin. The outer
membrane translocase TOM20 was only detected when neither deter-
gent nor protease was added. Endogenous MIC2622kDa behaved differ-
ently and showed a trypsin resistance that was similar to that of the
inner membrane proteins MIC60 and MIC27 (Fig. 2C). MIC2622kDa got
rapidly digested whereas a large fragment of MIC2622kDa (f) persisted
up to higher digitonin concentrations like the matrix protein HSP60.
The MIC2622kDa fragment and concomitantly HSP60 were only fully
degraded in the presence of Triton X-100. When we performed the
same experiment using mitochondria isolated from cells expressing
the N-terminally myc-tagged version of MIC26 we obtained a very
similar result (Fig. 2D). Albeit the fragment of myc-MIC2622kDa (f) was
not resolved verywell, we clearly observed that myc-MIC26 or the frag-
ment thereof persisted also at high digitonin concentrations indicatingthat the N-terminal part of the protein is protected from the protease
(Fig. 2D). The drop in signal intensity for both, MIC60 and myc-Mic26,
after adding trypsin in the absence of digitonin can be attributed to
the presence of mitochondria with ruptured outer membranes in this
preparation. Overall, we conclude that major parts of MIC2622kDa are
protected by the mitochondrial inner membrane from proteolysis. We
suggest that MIC2622kDa is a protein spanning the mitochondrial inner
membrane with major parts, including the N-terminus, located in the
mitochondrial matrix.
Next we performed an alkaline carbonate extraction experiment
using the heavy membrane fraction of 143B cells. MIC2622kDa was
found to persist within the membrane fraction like other membrane
spanning proteins such as MIC60, MIC27 and TOM20 (Fig. 2E). Glycosyl-
atedMIC2655kDawas partially released to the soluble fraction as indicated
by the soluble marker protein HSP60. We suppose that its sugar moiety
increases the solubility of the protein. Taken together, we could demon-
strate that MIC2622kDa is an integral protein of the mitochondrial IM.
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complex
In our previous study we showed that MIC26 and MIC27 comigrate
during native gel electrophoresis which is consistent with the interpre-
tation that both are constituents of the MICOS complex [34]. To test
whetherMIC2622kDa indeed represents a subunit of theMICOS complex
we performed Co-IP experiments using isolated mitochondria from143B cells. As a negative control we performed the Co-IP with
preimmune serum (PI). The experiments revealed that MIC2622kDa
interacts with MIC60, MIC27, and MIC10 when a MIC26 antibody was
used (Fig. 3A). We were also able to show these interactions in a
reciprocal manner using antibodies raised against MIC27 and MIC60
(Fig. 3B, C). No speciﬁc interaction was seen with other mitochondrial
proteins such as matrix located HSP60 or the OM translocase sub-
unit TOM20 (Fig. 3A–C). We conclude that a speciﬁc protein–protein
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Fig. 3.MIC2622kDa physically interacts with subunits of theMICOS complex. A–C, Co-IP experiments using the indicated antibodies or preimmune serum (PI). Indicatedmarkerswere used
for western blot analysis.
1557S. Koob et al. / Biochimica et Biophysica Acta 1853 (2015) 1551–1563interaction between MIC2622kDa with MIC60, MIC27, and MIC10 exists
conﬁrming that MIC2622kDa is a subunit of the MICOS complex.
3.4. MIC2622kDa reciprocally regulates MIC27 protein levels modulating
MIC10 and tafazzin levels
Next we investigated whether protein levels of MIC27 are affected
upon overexpression of myc-MIC26 (MIC26↑). MIC26 was transiently
overexpressed in 143B cells and the levels of MIC26 and MIC27 were
determined by western blot analysis. MIC26↑ cells showed a 2.6-fold
increase ofMIC2622kDa levels compared to control cells (Fig. 4A).Weob-
served thatMIC26↑ cells were signiﬁcantly reduced in their endogenous
levels of MIC27 reaching only levels of about 39% ± 13% compared to
control cells. In addition, overexpression of MIC27-FLAG (MIC27↑) by
~1.9-fold led to a decrease in MIC26 levels being only 47% ± 9% of
that of control cells (Fig. 4A). We could demonstrate that upon overex-
pression of either MIC26 or MIC27 the protein level of the respective
other homologous protein is decreased. This reciprocal inﬂuence of
MIC26 on MIC27 levels and vice versa was conﬁrmed also using HeLa
cells (data not shown). Next we analyzed whether other MICOS com-
plex constituents are affected in MIC26↑ or MIC27↑ cells. The core con-
stituent MIC60 as well as the MICOS subunit MIC19 remained both
unaffected in either MIC26↑ or MIC27↑ cells (Fig. 4B). Likewise, the
levels of subunit α of the F1FO-ATP synthase or of HSP60 were not
altered. However, both tafazzin (TAZ1) and MIC10 levels were found
to be signiﬁcantly increased about 1.5-fold upon overexpression of
MIC26 or MIC27 (Fig. 4B and C).
To further corroborate this we analyzed the behavior of MIC26 and
MIC27 protein levels upon MIC26 or MIC27 depletion in 143B cells.
MIC26 and MIC27 were constitutively downregulated by expressing
miRNAs targeted against their corresponding gene transcripts. Control
cells were transfected with an empty vector carrying an EmGFP con-
struct encoding for a ﬂuorescent marker. First, we determined that the
constitutive MIC26 knockdown (MIC26↓) cells showed a reduction of
MIC2622kDa protein levels to 22% ± 6% compared to control cells, like-
wise MIC27↓ cells showed a signiﬁcant reduction of MIC27 levels
to 57% ± 23% (Fig. 4D). Importantly, cells depleted for MIC26 showed
an increase in MIC27 protein levels up to 132% ± 6%. In line with
this, also cells depleted for MIC27 showed a 129% (±8%) increase in
MIC2622kDa levels. Downregulation of either MIC26 or MIC27 led to an
increase in the protein level of the respective homolog. Thus, the recip-
rocal regulation for these two homologous proteins was demonstrated
not only for overexpression but also for downregulation of either pro-
tein. The stable knockdown cells depleted for MIC26 or MIC27 were
also analyzed regarding their protein levels of other MICOS complexconstituents. Upon MIC26 or MIC27 depletion MIC60 and MIC19 were
not affected and behaved similar to the control proteins HSP60 and sub-
unit α of the F1FO-ATP synthase (Fig. 4E). Strikingly, MIC10 as well as
TAZ1 levels were decreased signiﬁcantly in cells depleted for MIC26 or
MIC27 (Fig. 4E and F). Similar to the data obtained by overexpression
also here the levels of MIC10 and TAZ1 are correlated to those of
MIC26 andMIC27. The speciﬁcity of theMIC26miRNAwas investigated
using an miRNA-resistant form of myc-MIC26. When the conventional
myc-MIC26 construct was expressed in MIC26↓ cells the protein levels
of myc-MIC26 and endogenous MIC26 clearly stayed decreased, and,
consistent with earlier results, the protein levels of MIC27 increased
and those of MIC10 decreased (see Figure 1A in [50]). However, when
a miRNA-resistant form of myc-MIC26 was expressed in this cell line
the protein levels of myc-MIC26 were not reduced conﬁrming that
this respective mRNA is not targeted by the miRNA used. Furthermore,
the miRNA-resistant form of myc-MIC26 prevented both an increase
of MIC27 and a reduction of MIC10 (see Figure 1A in [50]). This demon-
strates that the effects on other MICOS subunits observed by miRNA
againstMIC26 are speciﬁc to MIC26. These observations are consistent
with the idea that MIC26 and MIC27 inﬂuence each other, can act inde-
pendently in the same pathway, and thus are able to replace each other
functionally at least to some degree.
Moreover, we showed that the relative levels of mitochondrial
MIC2622kDa levels versus secretedMIC2655kDa levels can vary depending
on the cell line investigated (Fig. 1E). In this regard, we tested whether
the secreted levels of MIC2655kDa are altered upon depleting cells for
MIC26 or MIC27, respectively. We analyzed 143B cells depleted for
either of these proteins and performedwestern blot analysis. MIC26 de-
pletion did not lead to an increase or reduction of secreted MIC2655kDa
levels suggesting that in this cell line downregulation ofMIC26 primar-
ily affects the level of the mitochondrial MIC2622kDa isoform (see
Figure 1B in [50]). However, the protein levels of secreted MIC2655kDa
were clearly increased in 143B MIC27-depleted cells suggesting that
MIC27 is part of a regulatory pathway determining the amount of
MIC26 being secreted.
Taken together we could demonstrate that MIC26 and MIC27 pro-
tein levels reciprocally regulate each other. Conversely, they modulate
theMICOS complex subunitMIC10 aswell as the cardiolipin remodeling
enzyme tafazzin.
3.5. Overexpression of MIC26 impairs mitochondrial functions and
ultrastructure
Nextwe analyzedwhether overexpression ofMIC26 (MIC26↑) inﬂu-
encesmitochondrial morphology, generation of reactive oxygen species
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1558 S. Koob et al. / Biochimica et Biophysica Acta 1853 (2015) 1551–1563(ROS), mitochondrial respiration, and ultrastructure. Mitochondrial
morphology was markedly altered in HeLa cells overexpressing myc-
MIC26 compared to cells transfected with the empty plasmid. We
noted that mitochondria appeared more fragmented and showed a
swollen and roundish appearance (Fig. 5A). The number of cells show-
ing fragmented mitochondria was signiﬁcantly increased upon MIC26
overexpression compared to control (Fig. 5B). Next to this, we analyzed
mitochondrial ROS levels in MIC26↑ or MIC27↑ cells determining DHE
derived ﬂuorescence. As a positive control cells were starved for 4 h
using HBSS known to increase ROS levels [56]. Strikingly, overexpres-
sion of MIC26 induced a signiﬁcant increase in ROS levels compared tocontrol cells (Fig. 5C). A moderate, yet not signiﬁcant, increase was
also observed for cells overexpressingMIC27 consistent with our previ-
ous study [34]. Next we investigated the basal oxygen consumption
rate (OCR) and the extent to which the OCR is increased upon dissipa-
tion of the mitochondrial membrane potential in MIC26↑ or MIC27↑
cells. Both cell lines showed a considerably lower basal OCR compared
to control cells (Fig. 5DE) indicating that overexpression of either
construct strongly impairs bioenergetic functions of mitochondria.
Uncoupling of control cells using FCCP stimulated respiration by ~1.4
fold in control cells. However,MIC26↑ orMIC27↑ cellswere hardly stim-
ulated under these conditions suggesting a reduced activity of complex
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ized to control. Data represent mean ± SD, with *p b 0.05, **p b 0.01.
1559S. Koob et al. / Biochimica et Biophysica Acta 1853 (2015) 1551–1563IV (Fig. 5DE). Next we also addressed whether overexpression of
MIC26 altered mitochondrial ultrastructure. Indeed, we observed that
overexpression of MIC26 speciﬁcally resulted in cristae with swollen
or vesicle-like appearance in numerous mitochondrial sections (see
Figure 2 in [50]). This was not observed in control cells transfected
with an empty control plasmid. Overall these observations provide
several lines of evidence that mitochondrial functions are impaired
upon overexpression ofMIC26 orMIC27which is consistentwith earlier
studies [34,49].
3.6. Knockdown of MIC26 impairs mitochondrial respiration
Accordingly, we investigated the effects of constitutive knockdown
of MIC26 on the same physiological factors as performed for MIC26
overexpression. Mitochondrial network morphology was not affected
in stable MIC26 knockdown cells as mitochondria remained mostly
tubular (Fig. 6AB). NeitherMIC26↓ norMIC27↓ cells showed an increase
in DHE ﬂuorescence compared to cells transfected with the empty vec-
tor indicating that ROS levels remained constant (Fig. 6C). To investigate
whether there is also an impact on mitochondrial respiration in 143B
MIC26↓ or MIC27↓ cells we determined the oxygen consumption rate
(OCR) in those cells. Basal respiration was decreased to 43% ± 11% for
MIC26↓ and to 54% ± 14% for MIC27↓ cells (Fig. 6DE). Treatment of
mitochondria using FCCP stimulates respiration by uncoupling of ATP
synthesis from electron transport and induced an increase to maximal
respiration by 1.7-fold in control cells. However, in MIC26↓ and MIC27↓cells respiration was marginally stimulated. These results clearly show
that mitochondrial bioenergetic functions are impaired by depletion of
MIC26 or MIC27.
3.7. Loss of MIC26 is accompanied by alteration of mitochondrial
ultrastructure and a reduced number of crista junctions
MIC27-depletion was earlier shown to lead to concentric cristae
structures that appeared twirled and interconnected in contrast to the
normally rather lamellar arrangement [34]. We performed miRNA-
mediated knockdown experiments to examine the role of MIC26 on
mitochondrial architecture. Using electron microscopy we observed
that constitutive knockdown ofMIC26 alteredmitochondrial ultrastruc-
ture (Fig. 7A). CJs were frequently absent and cristae appeared broader
than in corresponding controls (Fig. 7A, c–f). Quantiﬁcation of the num-
ber of CJs per mitochondrion demonstrated a signiﬁcant reduction of CJ
abundance in MIC26-depleted cells. We conclude that MIC26 serves as
an important component ensuring formation of CJs.
4. Discussion
Apolipoproteins are well known to facilitate transport and redistri-
bution of lipids within the human body. They are commonly known as
constituents of lipoprotein particles (e.g. HDL, LDL, VLDLs) or as non-
lipoprotein associated free plasma proteins. Alterations in lipid trans-
port are linked to diabetes [57,58] and cardiovascular diseases [59,60].
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1560 S. Koob et al. / Biochimica et Biophysica Acta 1853 (2015) 1551–1563Two apolipoproteins, MIC26 (APOO) andMIC27 (APOOL), are unique in
the respect that for both proteins an intracellular, namely a mitochon-
drial, localization was reported. MIC27 was found in mitochondria as
a CL binding constituent of the MICOS complex [34]. For MIC26 both a
mitochondrial as well as a blood plasma localization were reported
[34,44,49]. Initially, MIC26 was only shown to be a secreted 55 kDa
glycosylated protein [44]. MIC26 levels were increased in the heart of
diabetic patients and in the plasma of patients suffering from acute cor-
onary syndrome [44,45,47]. It was also shown to promote cholesterol
efﬂux from macrophages [44]. Plasma MIC26 was thus suggested to
act in a protective manner against lipoapoptosis and arteriosclerosis
[44]. Still, a primary role in cholesterol transport was questioned as
a MIC26 overexpression mouse model did not reveal any alterations in
cholesterol levels and HDL lipid compositions. Moreover, a recent
study proposed that the 55 kDa isoform of MIC26 is also targeted to mi-
tochondria and that overexpression of MIC26 rather enhances fatty acid
metabolism, ROS production, and cardiac lipotoxicity [49]. Although
these apparently contradicting ﬁndings need further investigations, it
is well supported that MIC26 exists in mitochondria as well as in the
blood plasma. However, it was not resolved before (1) whether indeed
a glycosylated isoform of MIC26 localizes to mitochondria, (2) whether
another intracellular isoform of MIC26 exists that is targeted to mito-
chondria, and (3) what is the primary functional role of MIC26 in mito-
chondria. Here we show that MIC26 exists in three distinct isoforms:
(1) a glycosylated 55 kDa isoform that is present in light membranes
such as ER or Golgi apparatus, (2) a glycosylated 55 kDa isoform that
becomes secreted to the extracellular space, and a non-glycosylated22 kDa isoform that is exclusively found inmitochondria. To our knowl-
edge this is the ﬁrst example of a protein with a presence in these three
distinct locations. Moreover, this study identiﬁes the functional role
of the latter isoform as a constituent of the MICOS complex playing a
crucial role in determining the molecular architecture of cristae and
CJs. It was previously reported that MIC26 comigrates with the MICOS
complex in native gels [34] and that overexpression of MIC26 leads to
altered cristae morphology, including loss or discontinuity of cristae
andmitochondrial swelling [49]. A functional role of humanMIC2622KDa
in CJ formation was not reported before, but is now supported by the
following results of this study: (1) amyc-tagged 22 kDa isoform of
MIC26 which is apparently not glycosylated is located to mitochondria;
(2) MIC2622kDa was biochemically localized to the IM of mitochondria
exposing a large part to the matrix-side; (3) it physically interacts
with several subunits of the mammalian MICOS complex, such as
MIC60, MIC10, and MIC27; (4) its protein levels are antagonistically
regulated to MIC27 and are coregulated with the levels of MIC10;
(5) MIC26 overexpression impairs mitochondrial functions and alters
cristae morphology; (6) MIC26 depletion impairs mitochondrial func-
tion in a similar manner as MIC27 depletion; and ﬁnally (7) MIC26
knockdown impairs formation of CJs in mammalian cells. The fact that
MIC26 and MIC27, two proteins that are homologous to each other,
are antagonistically regulated raises the possibility that they have par-
tially overlapping or redundant functions. If this is indeed the case the
lack of one component, at least to some extent, can be compensated
which could for example still allow the assembly of theMICOS complex
in the absence of one subunit. At least such a scenario could explainwhy
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1561S. Koob et al. / Biochimica et Biophysica Acta 1853 (2015) 1551–1563in mammals depletion of MIC26 or MIC27 has rather moderate effects
on cristae morphology and why formation of crista junctions is appar-
ently not completely blocked. Still, as crista junction formation is clearly
impaired when the balanced expression of both isoforms is altered,
e.g. by depletion of human MIC26 as shown here, it is unlikely that
both proteins are functionally fully redundant. Also in baker's yeast
it was reported that only deletion of Mic27, but not of Mic26, affected
cristae morphology [36–38] suggesting different roles in crista junction
formation for these proteins. It should be noted here that based on
sequence homology it is currently not possible to decide whether
human MIC26 is orthologous to the yeast Mic26 or to Mic27. Taken to-
gether, in contrast to the situation in yeast it appears that in mammals
both proteins, MIC26 and MIC27, are important factors determining
formation of crista junctions.
We further demonstrate that MIC26 levels are positively correlated
to tafazzin levels. Tafazzin is required for cardiolipin acyl chain remod-
eling [30]. This suggests that MIC26 is involved in CL metabolism in mi-
tochondria. This is further supported by the fact that MIC26 interacts
with MIC27, a CL binding subunit of the MICOS complex, and that the
levels of these two homologous proteins are interdependent. Also in
baker's yeast the MICOS complex was recently linked to CL metabolism
as expression of a His-tagged variant of Mic12 or Mic26 in cells lacking
Aim24 resulted in reduced tafazzin levels and impaired CL remodeling
[61]. A possible link of CJ formation by the MICOS complex and CL-associated functions in mitochondria was recently discussed in detail
by our group [43].
In the light of our ﬁndings on the mitochondrial function of
MIC2622kDa we suggest that reported adverse effects of MIC26 overex-
pression on cardiac function [49] are linked to alterations in CLmetabo-
lism and mitochondrial CJ formation by the MICOS complex. So far, all
studies on MIC26 focused on the function of the 55 kDa form of MIC26
which was shown to be the glycosylated isoform mainly present
in HDL particles. In the present study we show that it is actually the
non-glycosylated, mitochondrial MIC2622kDa isoform that leads to
morphological alterations, increased ROS formation and a decrease in
mitochondrial respiration.We propose that in contrast to the prevailing
view on MIC26 function it is actually the mitochondrial MIC2622kDa
isoform that leads to cardiac lipotoxicity upon overexpression.
This does not exclude important physiological roles of the secreted
MIC2655kDa isoform, yet so far a major effect on cholesterol levels and
HDL composition in the plasma was not detected and further studies
are required [46].
How the ratio and the level of the different isoforms of MIC26 are
determined is an open question. It is well possible that after protein
synthesis a precursor competes for being targeted either to secretory
compartments or to mitochondria. The targeting signals according to
bioinformatic predictions are weak for each compartment and a kinetic
regulation could apply here. If indeed such a competitive mechanism
1562 S. Koob et al. / Biochimica et Biophysica Acta 1853 (2015) 1551–1563applies an impaired import of MIC2622kDa into mitochondria caused by
mitochondrial dysfunction may trigger an increase in secretion of
MIC2655kDa. This is at least consistent with MIC2655kDa levels being in-
creased in the blood plasma of patients suffering from acute coronary
syndrome or in animals fed by a high-fat diet [45,49], conditions that
are known to be linked to mitochondrial dysfunction [62,63]. Future
studies will have to address in more detail the interplay between the
different isoforms of MIC26 and how this is linked to human disorders
such as diabetes, obesity or cardiomyopathy.
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